vs
Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and RxSight, Inc. (RXST). Click either name above to swap in a different company.
Armour Residential REIT, Inc. is the larger business by last-quarter revenue ($50.4M vs $32.6M, roughly 1.5× RxSight, Inc.). Armour Residential REIT, Inc. runs the higher net margin — 420.2% vs -28.1%, a 448.3% gap on every dollar of revenue. On growth, Armour Residential REIT, Inc. posted the faster year-over-year revenue change (297.9% vs -18.9%). Over the past eight quarters, Armour Residential REIT, Inc.'s revenue compounded faster (108.0% CAGR vs 5.1%).
Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.
RxSight, Inc. is a medical technology company focused on developing and commercializing innovative intraocular lens solutions for patients undergoing cataract and refractive lens exchange procedures. Its flagship Light Adjustable Lens allows post-surgery power adjustment via a dedicated light delivery device, serving global ophthalmology care markets to improve post-operative visual outcomes for patients.
ARR vs RXST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | ||
|---|---|---|
| Revenue | $50.4M | $32.6M |
| Net Profit | $211.7M | $-9.2M |
| Gross Margin | — | 77.5% |
| Operating Margin | — | -34.8% |
| Net Margin | 420.2% | -28.1% |
| Revenue YoY | 297.9% | -18.9% |
| Net Profit YoY | 555.9% | -54.1% |
| EPS (diluted) | $2.43 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.4M | $32.6M | ||
| Q3 25 | $38.5M | $30.3M | ||
| Q2 25 | $33.1M | $33.6M | ||
| Q1 25 | $36.3M | $37.9M | ||
| Q4 24 | $12.7M | $40.2M | ||
| Q3 24 | — | $35.3M | ||
| Q2 24 | $7.0M | $34.9M | ||
| Q1 24 | — | $29.5M |
| Q4 25 | $211.7M | $-9.2M | ||
| Q3 25 | $159.3M | $-9.8M | ||
| Q2 25 | $-75.6M | $-11.8M | ||
| Q1 25 | $27.3M | $-8.2M | ||
| Q4 24 | $-46.4M | $-5.9M | ||
| Q3 24 | — | $-6.3M | ||
| Q2 24 | $-48.4M | $-6.1M | ||
| Q1 24 | — | $-9.1M |
| Q4 25 | — | 77.5% | ||
| Q3 25 | — | 79.9% | ||
| Q2 25 | — | 74.9% | ||
| Q1 25 | — | 74.8% | ||
| Q4 24 | — | 71.6% | ||
| Q3 24 | — | 71.4% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 70.1% |
| Q4 25 | — | -34.8% | ||
| Q3 25 | — | -40.1% | ||
| Q2 25 | — | -41.6% | ||
| Q1 25 | — | -28.2% | ||
| Q4 24 | — | -21.5% | ||
| Q3 24 | — | -26.1% | ||
| Q2 24 | — | -23.9% | ||
| Q1 24 | — | -36.2% |
| Q4 25 | 420.2% | -28.1% | ||
| Q3 25 | 413.5% | -32.4% | ||
| Q2 25 | -228.4% | -35.0% | ||
| Q1 25 | 75.2% | -21.6% | ||
| Q4 24 | -366.8% | -14.8% | ||
| Q3 24 | — | -17.9% | ||
| Q2 24 | -693.8% | -17.4% | ||
| Q1 24 | — | -30.8% |
| Q4 25 | $2.43 | $-0.22 | ||
| Q3 25 | $1.49 | $-0.24 | ||
| Q2 25 | $-0.94 | $-0.29 | ||
| Q1 25 | $0.32 | $-0.20 | ||
| Q4 24 | $-0.91 | $-0.14 | ||
| Q3 24 | — | $-0.16 | ||
| Q2 24 | $-1.05 | $-0.16 | ||
| Q1 24 | — | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $228.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3B | $275.7M |
| Total Assets | $21.0B | $311.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | $228.1M | ||
| Q3 25 | $44.2M | $227.5M | ||
| Q2 25 | $141.2M | $227.5M | ||
| Q1 25 | $49.1M | $229.3M | ||
| Q4 24 | $68.0M | $237.2M | ||
| Q3 24 | — | $237.1M | ||
| Q2 24 | $126.6M | $233.3M | ||
| Q1 24 | — | $125.4M |
| Q4 25 | $2.3B | $275.7M | ||
| Q3 25 | $2.1B | $276.0M | ||
| Q2 25 | $1.7B | $278.0M | ||
| Q1 25 | $1.7B | $279.3M | ||
| Q4 24 | $1.4B | $281.2M | ||
| Q3 24 | — | $277.3M | ||
| Q2 24 | $1.2B | $275.2M | ||
| Q1 24 | — | $163.9M |
| Q4 25 | $21.0B | $311.8M | ||
| Q3 25 | $19.4B | $308.5M | ||
| Q2 25 | $16.2B | $309.0M | ||
| Q1 25 | $15.5B | $313.0M | ||
| Q4 24 | $13.5B | $318.6M | ||
| Q3 24 | — | $310.5M | ||
| Q2 24 | $10.1B | $305.5M | ||
| Q1 24 | — | $183.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $124.2M | $-1.1M |
| Free Cash FlowOCF − Capex | — | $-2.3M |
| FCF MarginFCF / Revenue | — | -6.9% |
| Capex IntensityCapex / Revenue | — | 3.5% |
| Cash ConversionOCF / Net Profit | 0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-19.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.2M | $-1.1M | ||
| Q3 25 | $-37.8M | $-1.2M | ||
| Q2 25 | $25.0M | $-4.4M | ||
| Q1 25 | $101.5M | $-8.8M | ||
| Q4 24 | $261.5M | $-4.3M | ||
| Q3 24 | — | $650.0K | ||
| Q2 24 | $27.1M | $-4.0M | ||
| Q1 24 | — | $-9.3M |
| Q4 25 | — | $-2.3M | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | $-5.9M | ||
| Q1 25 | — | $-9.4M | ||
| Q4 24 | — | $-5.1M | ||
| Q3 24 | — | $-453.0K | ||
| Q2 24 | — | $-5.5M | ||
| Q1 24 | — | $-11.3M |
| Q4 25 | — | -6.9% | ||
| Q3 25 | — | -5.8% | ||
| Q2 25 | — | -17.6% | ||
| Q1 25 | — | -24.8% | ||
| Q4 24 | — | -12.7% | ||
| Q3 24 | — | -1.3% | ||
| Q2 24 | — | -15.9% | ||
| Q1 24 | — | -38.2% |
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 4.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 4.4% | ||
| Q1 24 | — | 6.7% |
| Q4 25 | 0.59× | — | ||
| Q3 25 | -0.24× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARR
Segment breakdown not available.
RXST
| Rxlal | $28.2M | 86% |
| LDD | $3.0M | 9% |
| Service Warranty Service Contracts And Accessories | $1.5M | 4% |